Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

26-12-2022

The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument

Auteurs: Qiang Zheng, Ingrid A. Cox, Barbara de Graaff, Julie A. Campbell, Tamera J. Corte, Ian Glaspole, Vidya Navaratnam, Peter Hopkins, Chris Zappala, Hasnat Ahmad, Ting Zhao, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

Gepubliceerd in: Quality of Life Research | Uitgave 6/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Little is known about the impact of co-morbidities on health-related quality of life (HRQoL) for people with idiopathic pulmonary fibrosis (IPF). We aimed to investigate the relative contribution of co-morbidities to HRQoL of people with IPF.

Methods

N = 157 participants were recruited from the Australian IPF Registry (AIPFR). Health state utilities (HSUs), and the super-dimensions of physical and psychosocial scores were measured using the Assessment of Quality of Life-8-Dimensions (AQoL-8D). The impact of co-morbidities on HRQoL was investigated using linear regression and general dominance analyses.

Results

A higher number of co-morbidities was associated with lower HSUs (p trend = 0.002). Co-morbidities explained 9.1% of the variance of HSUs, 16.0% of physical super-dimensional scores, and 4.2% of psychosocial super-dimensional scores. Arthritis was associated with a significant reduction on HSUs (β =  − 0.09, 95% confidence interval [CI] − 0.16 to − 0.02), largely driven by reduced scores on the physical super-dimension (β =  − 0.13, 95% CI − 0.20 to − 0.06). Heart diseases were associated with a significant reduction on HSUs (β =  − 0.09, 95% CI − 0.16 to − 0.02), driven by reduced scores on physical (β =  − 0.09, 95% CI − 0.16 to − 0.02) and psychosocial (β = -0.10, 95% CI − 0.17 to − 0.02) super-dimensions.

Conclusions

Co-morbidities significantly impact HRQoL of people with IPF, with markedly negative impacts on their HSUs and physical health. A more holistic approach to the care of people with IPF is important as better management of these co-morbidities could lead to improved HRQoL in people with IPF.
vorige artikel Correction: Development of a standard set of PROs and generic PROMs for Dutch medical specialist care
volgende artikel Comparative analysis of pediatric anxiety measures in clinical sample: evaluation of the PROMIS pediatric anxiety short forms
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Tran, T., Šterclová, M., Mogulkoc, N., Lewandowska, K., Müller, V., Hájková, M., Kramer, M. R., Jovanović, D., Tekavec-Trkanjec, J., Studnicka, M., Stoeva, N., Hejduk, K., Dušek, L., Suissa, S., & Vašáková, M. (2020). The European MultiPartner IPF registry (EMPIRE): Validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 21(1), 1–11.CrossRef
2.
Strand, M. J., Sprunger, D., Cosgrove, G. P., Fernandez-Perez, E. R., Frankel, S. K., Huie, T. J., Olson, A. L., Solomon, J., Brown, K. K., & Swigris, J. J. (2014). Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest, 146(3), 775–785.CrossRefPubMedPubMedCentral
3.
Cox, I. A., Otahal, P., Graaff, B., Corte, T. J., Moodley, Y., Zappala, C., Glaspole, I., Hopkins, P., Macansh, S., Walters, E. H., & Palmer, A. J. (2021). Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 27(3), 209–216.CrossRefPubMed
4.
Sheth, J. S., Xia, M., Murray, S., Martinez, C. H., Meldrum, C. A., Belloli, E. A., Salisbury, M. L., White, E. S., Holtze, C. H., & Flaherty, K. R. (2019). Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 148, 6–12.CrossRefPubMedPubMedCentral
5.
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. (2019). Comorbidities in idiopathic pulmonary fibrosis: An underestimated issue. European Respiratory Review, 28(153), 190044.CrossRefPubMedPubMedCentral
6.
Alhamad, E. H., Cal, J. G., Alrajhi, N. N., Aharbi, W. M., AlRikabi, A. C., & AlBoukai, A. A. (2020). Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis. Annals of Thoracic Medicine, 15(4), 208–214.CrossRefPubMedPubMedCentral
7.
Caminati, A., Madotto, F., Conti, S., Cesana, G., Mantovani, L., & Harari, S. (2021). The natural history of idiopathic pulmonary fibrosis in a large European population: The role of age, sex and comorbidities. Internal and Emergency Medicine, 16(7), 1793–1802.CrossRefPubMed
8.
Torrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C. (2019). The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: A multicentre observational study. European Respiratory Journal, 53(3), 1801587.CrossRefPubMed
9.
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., King, T. E., Jr., & Collard, H. R. (2012). A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine, 156(10), 684–691.CrossRefPubMed
10.
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford University Press.
11.
Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956.CrossRefPubMed
12.
Cox, I. A., Borchers Arriagada, N., De Graaff, B., Corte, T. J., Glaspole, I., Lartey, S., Walters, E. H., & Palmer, A. J. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. European Respiratory Review, 29(158), 200154.CrossRefPubMedPubMedCentral
13.
Richardson, J., Khan, M. A., Iezzi, A., & Maxwell, A. (2015). Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments. Medical Decision Making, 35(3), 276–291.CrossRefPubMed
14.
Richardson, J., Sinha, K., Iezzi, A., & Khan, M. A. (2014). Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Quality of Life Research, 23(8), 2395–2404.CrossRefPubMed
15.
Cox, I. A., De Graaff, B., Ahmed, H., Campbell, J., Otahal, P., Corte, T. J., Glaspole, I., Moodley, Y., Goh, N., Macansh, S., Walters, E. H., & Palmer, A. J. (2021). The impact of idiopathic pulmonary fibrosis on health state utility values: Evidence from Australia. Quality of Life Research, 30(9), 2615–2632.CrossRefPubMed
16.
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T., … Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139.CrossRefPubMedPubMedCentral
17.
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., Allan, H., Keir, G. J., Hayen, A., Cooper, W. A., Mahar, A. M., Ellis, S., Macansh, S., & Corte, T. J. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 1601592.CrossRefPubMed
18.
Lo, L. M. P., Taylor, B. V., Winzenberg, T., Palmer, A. J., Blizzard, L., Ahmad, H., Hussain, M. A., & Van Der Mei, I. (2021). Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. Journal of Neurology, 268(2), 569–581.CrossRefPubMed
19.
Ahmad, H., van der Mei, I., Taylor, B. V., Campbell, J. A., & Palmer, A. J. (2020). Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. Multiple Sclerosis and Related Disorders, 44, 102358.CrossRefPubMed
20.
Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., & Stocks, J. (2012). Multi-ethnic reference values for spirometry for the 3–95-yr age range: The global lung function 2012 equations. European Respiratory Journal, 40(6), 1324–1343.CrossRefPubMed
21.
Stanojevic, S., Graham, B. L., Cooper, B. G., Thompson, B. R., Carter, K. W., Francis, R. W., & Hall, G. L. (2017). Official ERS technical standards: Global lung function Initiative reference values for the carbon monoxide transfer factor for caucasians. European Respiratory Journal, 50(3), 1700010.CrossRefPubMed
22.
Luchman, J. N. (2021). Determining relative importance in stata using dominance analysis: Domin and domme. The Stata Journal: Promoting communications on statistics and Stata, 21(2), 510–538.CrossRef
23.
Azen, R., & Budescu, D. V. (2003). The dominance analysis approach for comparing predictors in multiple regression. Psychological Methods, 8(2), 129–148.CrossRefPubMed
24.
StataCorp. (2021). Stata Statistical Software: Release 17. StataCorp LLC.
25.
Campbell, J. A., Hensher, M., Neil, A., Venn, A., Otahal, P., Wilkinson, S., & Palmer, A. J. (2018). An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery. PharmacoEconomics - Open, 2(4), 443–458.CrossRefPubMed
26.
Collard, H. R., Ward, A. J., Lanes, S., Cortney Hayflinger, D., Rosenberg, D. M., & Hunsche, E. (2012). Burden of illness in idiopathic pulmonary fibrosis. Journal of Medical Economics, 15(5), 829–835.CrossRefPubMed
27.
28.
Maxwell, A., Özmen, M., Iezzi, A., & Richardson, J. (2016). Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. Quality of Life Research, 25(12), 3209–3219.CrossRefPubMed
29.
Lodder, M. C. (2004). Bone mineral density in patients with rheumatoid arthritis: Relation between disease severity and low bone mineral density. Annals of the Rheumatic Diseases, 63(12), 1576–1580.CrossRefPubMedPubMedCentral
30.
Ikezoe, K., Handa, T., Tanizawa, K., Kubo, T., Oguma, T., Hamada, S., Watanabe, K., Aihara, K., Sokai, A., Nakatsuka, Y., Muro, S., Nagai, S., Uno, K., Chin, K., Fukui, M., Hirai, T., & Mishima, M. (2015). Bone mineral density in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 109(9), 1181–1187.CrossRefPubMed
31.
Caffarelli, C., Gonnelli, S., Tomai Pitinca, M. D., Francolini, V., Fui, A., Bargagli, E., Refini, R. M., Bennett, D., Nuti, R., & Rottoli, P. (2016). Idiopathic pulmonary fibrosis a rare disease with severe bone fragility. Internal and Emergency Medicine, 11(8), 1087–1094.CrossRefPubMed
32.
Agrawal, A., Verma, I., Shah, V., Agarwal, A., & Sikachi, R. R. (2016). Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable & Rare Diseases Research, 5(2), 70–75.CrossRef
33.
Baumeister, H., Kriston, L., Bengel, J., & Härter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. Journal of Clinical Epidemiology, 63(5), 558–565.CrossRefPubMed
34.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W. (2014). A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 370(22), 2083–2092.CrossRefPubMed
35.
Richeldi, L., Du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., … Collard, H. R. (2014). Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 370(22), 2071–2082.CrossRefPubMed
36.
Kaunisto, J., Salomaa, E.-R., Hodgson, U., Kaarteenaho, R., Kankaanranta, H., Koli, K., Vahlberg, T., & Myllärniemi, M. (2019). Demographics and survival of patients with idiopathic pulmonary fibrosis in the finnishipf registry. ERJ Open Research, 5(3), 00170–02018.CrossRefPubMedPubMedCentral
Metagegevens
Titel
The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument
Auteurs
Qiang Zheng
Ingrid A. Cox
Barbara de Graaff
Julie A. Campbell
Tamera J. Corte
Ian Glaspole
Vidya Navaratnam
Peter Hopkins
Chris Zappala
Hasnat Ahmad
Ting Zhao
Sacha Macansh
E. Haydn Walters
Andrew J. Palmer
Publicatiedatum
26-12-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03331-8

Andere artikelen Uitgave 6/2023

Comparing the effects of reduced social contact on psychosocial wellbeing before and during the COVID-19 pandemic: a longitudinal survey from two Norwegian counties

  • Open Access

Estimating meaningful thresholds for multi-item questionnaires using item response theory

  • Open Access

What is important to adults after lower limb reconstruction surgery: a conceptual framework

  • Open Access

Comparative analysis of pediatric anxiety measures in clinical sample: evaluation of the PROMIS pediatric anxiety short forms

Correction: Development of a standard set of PROs and generic PROMs for Dutch medical specialist care

  • Open Access
  • Correction

Development of a standard set of PROs and generic PROMs for Dutch medical specialist care

  • Open Access